A welcome return of shareholder activism sees a curious battle develop for the one-hit wonder Exelixis.
With $219bn in accumulated sales the Abbvie mega-blockbuster is biopharma’s best-selling drug. Can Keytruda do better?
Leqembi's accelerated approval sees Eisai upholding its part of the bargain, setting a reasonable price and moving fast with confirmatory data.
As Zantac litigation risk wipes $43bn off public company valuations are investors right to be worried?
New extended consensus forecasts from Evaluate Pharma show Roche edged out of first place by Abbvie as new blood replaces Humira.